⌘K
t
Ergomed plc announced it will release its interim results for the six months ending 30 June 2023 on 26 September 2023. On the same day, the Company's Executive Management team will host an in-person briefing for analysts at 11:00 am BST, which will also be available via live webcast and conference call.
| Date | 15 Sept 2023 |
| Time | 07:00:06 |
| Category | Results |
| ID | 5253M |
PRESS RELEASE
Ergomed
Notice of Interim Results
Guildford, UK - 31 August 2023: Ergomed plc, (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, will announce its interim results for the six months ending 30 June 2023 on 26 September 2023.
Members of the Company's Executive Management team including Dr Miroslav Reljanović (Executive Chairman), Jonathan Curtain (Chief Financial Officer) and Keith Byrne (SVP, Capital Markets & Strategy) will host an in-person briefing for analysts at 11.00 am BST on the day of the results at the offices of Numis, at 45 Gresham Street, London, EC2V 7BF. There will also be a live webcast and conference call with a Q&A session. The webcast will be shared on the Investor Portal section of the Company's website at www.ergomedplc.com.
ENDS
Enquiries:
|
Ergomed plc |
Tel: +44 (0) 1483 402 975 |
|
Miroslav Reljanović (Executive Chairman) |
|
|
Jonathan Curtain (Chief Financial Officer) Keith Byrne (Senior Vice President, Capital Markets and Strategy) |
|
|
|
|
|
Numis (Nominated Adviser and Joint Broker) |
Tel: +44 (0) 20 7260 1000 |
|
Freddie Barnfield / Euan Brown / Jack McLaren |
|
|
Peel Hunt (Joint Broker) James Steel / Dr Christopher Golden |
Tel: +44 (0) 20 7418 8900
|
|
|
|
|
Consilium Strategic Communications - for UK enquiries |
Tel: +44 (0) 20 3709 5700 |
|
Chris Gardner / Matthew Neal |
|
|
|
|
|
|
|
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com.